Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet
Novo Nordisk on Tuesday forecast a fall in 2026 sales and operating profit on an adjusted basis, pushing its U.S.-listed shares down about 12% in afternoon trade. The Danish drugmaker said it expects adjusted sales growth of -5% to -13% at constant exchange rates, which strip out currency swings, and the same range for adjusted operating profit.